MedTrace Logo

Physiotherapy Treatment With Capacitive Resistive Monopolar Radiofrecuency in Young Women With Dyspareunia

NCT05844189 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-05-06

No results posted yet for this study

Summary

The hypothesis of this study is that capacitive-resistive monopolar radiofrecuency (CRMRF) with vaginal manual physiotherapy improves sexual health in young women suffering from dyspareunia (pain during sexual intercourse). The realization of studies that help to know the therapeutic possibilities in the field of dyspareunia seems necessary, taking into account the number of women affected, as well as the deficits of scientific evidence in this field.

The main objective of this study is to analyze whether the use of CRMRF brings additional benefits to the results of manual therapy on dyspareunia in young women.

Likewise, it intends to analyze the data for two secondary objectives:

1. Analyze changes in different areas of women's sexual function in young people with dyspareunia through treatment (Desire, arousal, lubrication, orgasm, satisfaction and pain).
2. Study if the use of CRMRF is an added benefit in personal perception while receiving treatment.

Conditions

  • Dyspareunia; Female

Interventions

PROCEDURE

Physical therapy modalities on pelvic floor (manual therapy)

Intravaginal treatment (perineal massage)

DEVICE

CRMRF

CRMRF application on pelvic floor: * Externally over the urogenital triangle of the patient, * Intracavitary application (intravaginal) * Externally over the urogenital triangle of the patient while the physical therapist performs the intracavitary manual therapy (intravaginal), The device used is named "Intradermik" and it is the portable CRMRF device of the brand RÖS'S Estética SL. It has these features: * Frequency: 448kHz * Capacitive power: 450 voltamperes * Resistive power: 200 watts

DEVICE

Sham CRMRF

The physical therapist applies the same treatment as the Treatment Group but the device is switched off.

Sponsors & Collaborators

  • Escoles Universitaries Gimbernat

    lead OTHER

Principal Investigators

  • Anna Abelló Pla, MSc · Escoles Universitaries Gimbernat

  • Jordi Esquirol Caussa, PhD · Escoles Universitaries Gimbernat

  • Judit Lleberia · Universitat Autònoma de Barcelona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-05
Primary Completion
2023-02-09
Completion
2023-02-09

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05844189 on ClinicalTrials.gov